Introduction 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is a popular recreational drug that modulates brain monoamines by inhibiting their reuptake (White et al., 1996; Kalant, 2001; De la Torre et al., 2004; Nagai et al., 2007; Doly et al., 2009) and degradation (Leonardi and Azmitia, 1994 ). The serotonergic system seems to be the primary target of MDMA action, although dopamine also plays an important role (Benturquia et al., 2008; NIDA, 2010; Stove et al., 2010) .
Typical clinical effects of MDMA include euphoria, elation and sociability (Parrott, 2007; Bedi et al., 2009; Stove et al., 2010) . MDMA can evoke adverse effects, including anxiety, depression, psychoses and cognitive deficits (Hall and Henry, 2006; Control, 2009; NIDA, 2010) . The behavioral effects of acute MDMA have been extensively investigated in various animal models. In rodents, MDMA induces robust hyperlocomotion (Benturquia et al., 2008; Colussi-Mas and Schenk, 2008; Stove et al., 2010) and anxiety (Lin et al., 1999; Ho et al., 2004) .
Earlier research has used the zebrafish as a model sensitive to various pharmacological manipulations, including the hallucinogens lysergic acid diethylamide (LSD) and salvinorin A (Braida et al., 2007; Grossman et al., 2010) . As MDMA has not yet been tested in zebrafish, we examined its behavioral effects on this species. Finally, published rodent data show that psychedelic agents (e.g. LSD and MDMA), elevate the expression of c-fos, serving as a marker of neuronal activation that correlates with behavioral alterations (Salzmann et al., 2003; Benturquia et al., 2008; Reissig et al., 2008) . On the basis of earlier studies validating brain c-fos analyses in zebrafish (Baraban et al., 2005; Wong et al., 2010b) , we also examined the effects of MDMA on c-fos expression.
Methods

Subjects and housing
A total of 142 adult (5-7-month-old) male and female wild-type (short-fin) zebrafish were obtained from a local commercial distributor (50 Fathoms, Metairie, Louisiana, USA). All fish were housed in groups of 20-30 fishes per 40 l tank. The tanks were filled with filtered system water and maintained at 25-271C on a 14 : 10-h cycle. All fish used in this study were experimentally naive, and fed Tetramin Tropical Flakes twice daily. Animal experiments and care adhered to institutional and national regulations.
Behavioral testing
Behavioral testing was done between 11 : 00 and 15 : 00 h using tanks with water adjusted to the holding room temperature. To avoid the test battery effect, each experiment was carried out on a separate cohort. Zebrafish behavior was recorded by two trained observers (interrater reliability > 0.85) blinded to the treatments, and analyzed using Ethovision XT7 (Noldus IT, Wageningen, The Netherlands).
Experiment 1 tested zebrafish behavior in the standard, 6-min novel tank test following a 20-min pretreatment with varying doses (0.25-120 mg/l) of MDMA. Experiment 2 used mild-to-high effective doses (40, 80 and 120 mg/l, established in Experiment 1) and assessed rapid MDMA action, exposing zebrafish to a 30-min novel tank filled with drug-treated water, similar to the protocol described previously for LSD (Grossman et al., 2010) .
The novel tank test, used to assess zebrafish anxiety and locomotion (Levin et al., 2007; Bencan et al., 2009; Egan et al., 2009) , was a 1.5 l trapezoidal tank (15 height Â 28 top Â 23 bottom Â 7 cm width; Aquatic Habitats, Apopka, Florida, USA; Fig. 1b ) maximally filled with water and divided into two equal virtual horizontal portions [top and bottom (Egan et al., 2009) ]. The following endpoints were assessed in this paradigm: latency (s), entries to and Behavioral effects of acute 20-min exposure to 3,4-methylenedioxymethamphetamine (MDMA) on zebrafish tested in the standard 6-min novel tank test [Experiment 1; n = 27 (controls), 28 (10 mg/l), 12 (40 mg/l), 27 (80 mg/l) and 12 (120 mg/l)]. (a) Manually recorded behavioral endpoints [*P < 0.05, ***P < 0.001, # P = 0.05-0.01 (trend) vs. control; post-hoc Tukey test for significant ANOVA data]. (b) Two-dimensional traces generated using Ethovision XT7 software and a side-view camera. Two-dimensional traces were examined for each experimental cohort, rated from 1 to n (based on similarity to each other), and the middle trace was selected as representative, to best illustrate the typical patterns of zebrafish locomotion. (c) Habituation (per-minute distribution) of zebrafish behavioral activity (*P < 0.05, ***P < 0.005, minute 1 vs. minute 6 of the respective drug group, U-test).
time spent (s) in the upper portion, the frequency of erratic movements (sharp changes in direction, and unorganized spontaneous darting), as well as the frequency and duration (s) of freezing bouts [absence of movement, except for eyes and gills, for > 2 s (Egan et al., 2009) ]. Once manual data were generated for each minute of the test in Experiment 1, we examined intrasession habituation of zebrafish behavior by comparing behavioral scores for the first and last minutes of the test (Wong et al., 2010a) .
Video tracking
Recorded videos were analyzed using Ethovision XT7 (Noldus IT), as described previously (Cachat et al., 2010a; Grossman et al., 2010; Wong et al., 2010a) . The exported 'side view' two-dimensional traces were independently rated on a consensus basis from 1 to n (based on similarity to each other) by three trained observers blinded to the treatments. The middle trace was selected as representative for the group, to illustrate the two-dimensional spatial pattern of swimming activity (Grossman et al., 2010) .
Pharmacological manipulations
MDMA for this study was obtained through the NIDA Drug Supply Program. MDMA doses (40-120 mg/l) were chosen based on our pilot studies with a wide range of doses (0.25-120 mg/l). A standard 20-min pretreatment time was chosen here based on our pilot experiments with MDMA and other similar hallucinogenics (Grossman et al., 2010; Stewart et al., 2011a) . Pilot testing of the dose range in the novel tank showed effects of MDMA at doses between 40 and 120 mg/l ( Fig. 1 ), but an absence of effects at smaller doses (data not shown). Drug exposure was done by immersing individual zebrafish in a 1-l plastic beaker for 20 min before the testing (Experiment 1) or into a 1.5-l novel tank for 30 min during the testing (Experiment 2). Control fish were exposed to drug-free facility water for the same treatment time.
c-fos expression assay
Real time-PCR was performed for zebrafish c-fos mRNA in separate cohorts of animals exposed for 20 min to either drug-free water or to a behaviorally active dose (40 and 80 mg/l) of MDMA. The brains were dissected, with two brains combined per sample (six samples per group) for RNA extraction. cDNA was synthesized using random primers and iScript Select cDNA Synthesis Kit (Bio Rad, California, USA). For quantitative-PCR, cDNA was amplified with c-fos forward and reverse primers (Tang et al., 2007) .
Statistical analysis
Data were analyzed using one-way analysis of variance (factor: dose) followed by post-hoc Tukey testing for significance. Intra-session habituation (minute 1 vs. minute 6) data were tested using the paired U-test.
Experiment 2 data were analyzed using one-way analysis of variance (factor: dose) with repeated measures (test minutes 1-30) followed by post-hoc Tukey testing (vs. respective minute in the control group) for significance. c-fos expression data were assessed using the nonpaired U-test (control vs. respective drug-treated group). Data were expressed as mean ± standard error of the mean.
Significance was set at P value of less than 0.05.
Results
In Experiment 1, acute exposure to MDMA dosedependently effected novel tank behavior, modulating latency to the top, top transitions, time spent in top and the number of erratic movements [F(4,105) = 7.9, 6.9, 23.3 and 5.9, respectively; P < 0.001] as well as freezing bouts and duration [F(4,105) = 2.8 and 3.5, P < 0.05; Fig. 1a ]. There was a dose-dependent reduction in latency to top, top transitions and erratic movements, as well as an increase in time spent in top (Fig. 1a ). These behavioral profiles were also evident in computergenerated two-dimensional traces of zebrafish swimming, showing a dose-dependent increase in top dwelling in MDMA-treated fish (Fig. 1b) .
Interesting effects were observed for per-minute distribution of zebrafish activity that reflects intrasession habituation, particularly sensitive to various psychotropic drugs (Wong et al., 2010a) . Analysis of fish behavior in Experiment 1 showed robust intrasession habituation in control zebrafish, with significant minute 1 versus minute 6 differences for the number of top entries and time in top (P < 0.0005, U-test), as well as freezing bouts and duration (P < 0.05, U-test). There was no difference between 1 versus 6 min for erratic movements in control fish, consistent with earlier studies on the lack of intrasession habituation of this behavior (Wong et al., 2010a) . In contrast, MDMA exposure at 40, 80 and 120 mg/l markedly impaired zebrafish habituation, yielding no significant differences for minute 1 versus minute 6 data for the number of top entries, time in top, freezing bouts and freezing duration (Fig. 1c) . Erratic movements, unaffected in controls, showed no habituation in any of the MDMA-treated fish cohorts (data not shown).
Experiment 2 examined the immediate effects of MDMA using a 30-min novel tank test filled with drug-treated water. Although most behaviors were similar to those observed in Experiment 1, Fig. 2 shows that MDMA at 40 and 80 mg/l rapidly affected zebrafish behavior, within 5-10 min evoking typical top dwelling responses reported in Experiment 2. Similarly, there were no anxiogenic effects or behavioral inhibition, as the drug-exposed fish displayed top dwelling and lower immobility throughout this test.
Finally, acute 20-min exposure to moderate behaviorally active doses of MDMA affected brain c-fos expression, causing a 12.3-fold (not significant) elevation at 40 mg/l and a significant 26.6-fold increase at 80 mg/l (P < 0.01, U-test).
Discussion
This study is the first report on the effects of MDMA in zebrafish, showing increased top dwelling, reduced immobility, impaired intrasession habituation and elevated brain c-fos expression. Although MDMA induces predominantly pleasant effects in humans (Liechti et al., 2000; Parrott, 2007; Bedi et al., 2009) , it evokes hyperlocomotion and anxiety in rodents (Gurtman et al., 2002; Navarro et al., 2004; Sumnall et al., 2004; Faria et al., 2006) . In the zebrafish novel tank paradigm, increased top dwelling typically implies reduced anxiety (Levin et al., 2006; Egan et al., 2009; Cachat et al., 2010b) . Similar to MDMA action in humans, our study did not find anxietylike behavior in zebrafish (Figs 1 and 2) . It is possible that other factors play a role in the reduced apparent anxiety of our zebrafish. For example, anxiolytic manipulations usually increase several 'top' behaviors, including both time spent and the number of entries to top (Levin et al., 2006; Egan et al., 2009; Cachat et al., 2010b) . In this study, the number of top entries was significantly reduced (Fig. 1) , implying that top dwelling observed here may differ from a typical zebrafish anxiolytic response.
One possibility for this can be a serotonin syndrome-like state induced by serotonergic drugs in zebrafish . Similar 'surfacing' behavior was induced by other serotonergic drugs in this (Egan et al., 2009; Grossman et al., 2010; Sackerman et al., 2010; Stewart et al., 2011b) and other aquatic species (Abramson et al., 1962) . Alternatively, given the known properties of MDMA, increased top dwelling may also represent zebrafish disorientation and/or hallucinogenic-like states. For example, similar phenotypes were induced in zebrafish by other hallucinogens, such as LSD (Grossman et al., 2010) , salvinorin A (Braida et al., 2007) and ketamine (Zakhary et al., 2010) , lending indirect support to this notion.
The behavioral effects of MDMA strikingly resemble the effects of LSD, another psychedelic drug previously tested in zebrafish (Grossman et al., 2010) . Effective doses of MDMA identified in this study (40-120 mg/l) were 450-800 times higher than the effective doses of LSD (50-250 mg/l) in zebrafish (Grossman et al., 2010; Stewart et al., 2011b) . In humans, approximately 0.4-1 mg/kg LSD is generally sufficient to produce strong behavioral effects, compared with approximately 0.4-2 mg/kg (1000-2000 times higher) doses of a less potent MDMA (Control, 2007 (Control, , 2009 . Similar relative efficacy of these two drugs in zebrafish was close to that observed in humans, strongly supporting the translational value of zebrafish models for drug abuse research.
In line with earlier studies on zebrafish habituation (Wong et al., 2010a) , MDMA altered zebrafish habituation, maintaining locomotion at a constant level throughout the test (Fig. 1) . Although the ability of MDMA to impair habituation has also been reported in rodents (Gold and Koob, 1989; Kehne et al., 1992; Scearce-Levie et al., 1999) , other factors (e.g. drug-induced hyperlocomotion) may also contribute to this phenotype.
Mounting experimental evidence links MDMA behavioral effects to altered expression of brain c-fos. For example, MDMA increases c-fos and Fos in multiple areas of rodent brain (Stephenson et al., 1999; Salzmann et al., 2003; Colussi-Mas and Schenk, 2008) . Similar effects have been reported for LSD (Gresch et al., 2002; Reissig et al., 2008) .
In general, elevated zebrafish c-fos following the acute MDMA exposure reported here parallels rodent c-fos evidence, and zebrafish LSD data (own unpublished observations).
In summary, our study showed that 40-120 mg/l of MDMA evokes robust behavioral responses in zebrafish (Figs 1 and 2) , paralleling some animal and clinical effects of this drug. MDMA also induced physiological responses in zebrafish, elevating brain c-fos expression, similar to its effects in rodents. Expanding previous zebrafish reports using various psychotropic agents, such as LSD, salvinorin A, ketamine and dizocilpine (Swain et al., 2004; Braida et al., 2007; Grossman et al., 2010; Seibt et al., 2010; Zakhary et al., 2010) , this MDMA study supports high sensitivity of this aquatic model to hallucinogenic drugs.
